' Unprecedented ' 3-Year Sustained Survival in SCLC With New Combo ' Unprecedented ' 3-Year Sustained Survival in SCLC With New Combo

The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news